Floatz logo

Retifanlimab

Squamous Cell Carcinoma of the Anal Canal

Incyte Corporationmonoclonal_antibodyPhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Squamous Cell Carcinoma of the Anal Canal cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 3BB
Carboplatin
Incyte Corporation
Phase 3BB
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
M.D. Anderson Cancer Center
Phase 2B
MITOMYCIN C
National Cancer Institute (NCI)
Phase 2CCC

View all 11 →

Same molecule, other indications

Retifanlimab is also rated in:

urothelial carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
63 / 100
View asset →
non-small cell squamous lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →